Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pegvisomant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Pegvisomant. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-004904-19 Sponsor Protocol Number: 04_ENDO_44 Start Date*: 2005-07-11
    Sponsor Name:Christie Hospital
    Full Title: A two-centre, open label study of weekly pegvisomant treatment for patients with acromegaly
    Medical condition: This study will investigate the efficacy of once-weekly pegvisomant treatment in patients with acromegaly who have already achieved disease control on daily pegvisomant. The attraction of once wee...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000344-10 Sponsor Protocol Number: 06_ENDO_49 Start Date*: 2006-06-08
    Sponsor Name:Christie Hospital
    Full Title: Multi-centre study of cabergoline alone and in combination with pegvisomant in the management of active acromegaly
    Medical condition: acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005585-12 Sponsor Protocol Number: 1 Start Date*: 2007-12-20
    Sponsor Name:Department of Internal Medicine of the University of Munich
    Full Title: Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akrom...
    Medical condition: acromegaly (= growth hormone hypersecretion mostly caused by a pituitary adenoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001108-35 Sponsor Protocol Number: NRA 6290010 Start Date*: 2006-07-03
    Sponsor Name:Clinic of University of Wuerzburg
    Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY
    Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061835 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004386-24 Sponsor Protocol Number: PEGACRO Start Date*: 2015-12-04
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Effect of GH receptor antagonist on insulin resistance associated with acromegaly
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004231-31 Sponsor Protocol Number: MEC2011pegvqol Start Date*: 2013-07-22
    Sponsor Name:Erasmus University Medical Centre Rotterdam
    Full Title: Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF1 levels has been normalized by long-acting somatostatin analogues
    Medical condition: acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000265-43 Sponsor Protocol Number: München/CS04 Start Date*: 2018-05-30
    Sponsor Name:Max-Planck-Institut für Psychiatrie
    Full Title: A randomized, placebo-controlled trial comparing the treatment effect of Pegvisomant and the SSRI Escitalopram on depressive acromegalic patients
    Medical condition: Acromegalie with depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-012769-74 Sponsor Protocol Number: A4021040 Start Date*: 2009-09-02
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 110017
    Full Title: PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORS
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049280 Solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-000297-72 Sponsor Protocol Number: 2-55-52030-727 Start Date*: 2007-04-24
    Sponsor Name:BEAUFOUR IPSEN Pharma
    Full Title: Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) DE (Completed) CZ (Completed) DK (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002219-41 Sponsor Protocol Number: NL49517 Start Date*: 2015-07-22
    Sponsor Name:Erasmus Medical Centre
    Full Title: A prospective single-centre double blind randomized study on the efficacy and safety of 4 weekly pasireotide LAR administration in combination with or without weekly pegvisomant in previously contr...
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001190-25 Sponsor Protocol Number: A6291015 Start Date*: 2004-12-17
    Sponsor Name:Pfizer Ltd
    Full Title: A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensi...
    Medical condition: Diabetic nephropathy DN (Diabetes mellitus (DM) type I and type II with renal manifestations). MedDRA classification code : 10061835, 10045236 and 10045250 (Version 7.0, Level LLT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002919-24 Sponsor Protocol Number: CSMS995BDE16 Start Date*: 2006-02-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of...
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    M15 10000599 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003741-33 Sponsor Protocol Number: NRA6290020 Start Date*: 2007-12-17
    Sponsor Name:Barts and the London NHS Trust
    Full Title: A Study To Determine The Optimum Serum IGF-I Range In Patients With Acromegaly Treated With Pegvisomant
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005852-42 Sponsor Protocol Number: CSMS995BIC03 Start Date*: 2007-04-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist i...
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000831-34 Sponsor Protocol Number: GoforGH Start Date*: 2022-01-11
    Sponsor Name:Medical University of Vienna
    Full Title: InvestiGating the rOle of Growth Hormone in hepatic lipid metabolism in humans
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023674-39 Sponsor Protocol Number: AKRO1 Start Date*: 2014-08-05
    Sponsor Name:Österreichisches Akromegalie Register
    Full Title: Evaluation of a standardized treatment regimen for acromegaly: A multi centre intervention study
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005244-25 Sponsor Protocol Number: GH-2007-228 Start Date*: 2008-01-31
    Sponsor Name:Aarhus University Hospital, Department M
    Full Title: Co-treatment with pegvisomant and a somatostatin analogue (SA) in SA-responsive acromegalic patients: impact on insulin sensitivity, glucose tolerance, and pharmacoeconomics
    Medical condition: Acromegaly Insulin resistence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    9.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004259-22 Sponsor Protocol Number: ISIS766720-CS2 Start Date*: 2018-06-05
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-000675-20 Sponsor Protocol Number: ISIS766720-CS5 Start Date*: 2020-11-04
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherap...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) PL (Completed) LV (Prematurely Ended) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-003147-30 Sponsor Protocol Number: 1103-CT02 Start Date*: 2012-11-20
    Sponsor Name:Antisense Therapeutics Ltd
    Full Title: A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 06:37:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA